Objective: To assess the efficacy and safety of modified Guizhi Shaoyao Zhimu Tang (GSZT) with the Western medicines in treating rheumatoid arthritis. Methods: All the relevant studies were collected by searching the ...Objective: To assess the efficacy and safety of modified Guizhi Shaoyao Zhimu Tang (GSZT) with the Western medicines in treating rheumatoid arthritis. Methods: All the relevant studies were collected by searching the Pubmed, Web of science, Embase, Cochrane Library, SpringerLink, China National Knowledge Infrastructure (CNKI), VIP Journals database, and Wanfang database from their inception to October 2017. After the assessment, the eligible ones were subject to Jadad score. The meta-analysis was conducted by RevMan 5.3 software. Results: Totally 10 randomized controlled trials (RCTs) involving 962 patients were enrolled. The clinical efficacy of analysis showed that modified GSZT with the Western medicines can significantly improve the clinical total effective rate [OR = 4.64, 95%CI (3.03, 7.12), P −14.58, 95%CI (−16.49, −12.68), P −12.62 95%CI (−18.69, −6.54), P −49.88, 95%CI (−77.6, −22.09), P −5.34, 95%CI (−5.86, −4.82), P < 0.001]. The adverse events had been seen in both of the two groups, however, the clinical symptoms of the group on modified GSZT with the Western medicines were obviously reduced than the other one [OR = 0.25, 95%CI (0.10, 0.61), Z = 3.06, P < 0.01]. This system review shows that the modified GSZT with the Western medicines improved the clinical efficacy, symptoms and the blood biochemical indicators were improved significantly than that of Western medicines alone on rheumatoid arthritis. At the same time, it can reduce adverse effects and enhance safety.展开更多
目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服...目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服利用度(oral bioavailability,OB)、类药性(drug-likeness,DL),药物半衰期(drug half-life,HL)检索柴胡桂枝干姜汤中柴胡、桂枝、干姜、黄芩、瓜蒌根、牡蛎、炙甘草的候选化合物及作用靶点信息,并通过Uniprot数据库将靶点校正为基因名;运用Genecards数据库获取腺样体肥大的相关靶点与基因,利用VENNY图获得柴胡桂枝干姜汤与腺样体肥大的交集靶点;STRING数据库来构建蛋白质相互作用PPI网络图;David数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和KEGG通路富集分析;Cytoscape软件进行网络靶点特性分析。结果:筛选出柴胡桂枝干姜汤候选化合物65个,转化为有效靶点288个,得到腺样体肥大相关靶点781个,匹配得到共有靶点118个。GO富集主要涉及597个生物学过程、60个细胞组成和106个分子功能,KEGG通路分析主要涉及112条通路。结论:柴胡桂枝干姜汤治疗腺样体肥大是通过多靶点多通路发挥作用的。展开更多
文摘Objective: To assess the efficacy and safety of modified Guizhi Shaoyao Zhimu Tang (GSZT) with the Western medicines in treating rheumatoid arthritis. Methods: All the relevant studies were collected by searching the Pubmed, Web of science, Embase, Cochrane Library, SpringerLink, China National Knowledge Infrastructure (CNKI), VIP Journals database, and Wanfang database from their inception to October 2017. After the assessment, the eligible ones were subject to Jadad score. The meta-analysis was conducted by RevMan 5.3 software. Results: Totally 10 randomized controlled trials (RCTs) involving 962 patients were enrolled. The clinical efficacy of analysis showed that modified GSZT with the Western medicines can significantly improve the clinical total effective rate [OR = 4.64, 95%CI (3.03, 7.12), P −14.58, 95%CI (−16.49, −12.68), P −12.62 95%CI (−18.69, −6.54), P −49.88, 95%CI (−77.6, −22.09), P −5.34, 95%CI (−5.86, −4.82), P < 0.001]. The adverse events had been seen in both of the two groups, however, the clinical symptoms of the group on modified GSZT with the Western medicines were obviously reduced than the other one [OR = 0.25, 95%CI (0.10, 0.61), Z = 3.06, P < 0.01]. This system review shows that the modified GSZT with the Western medicines improved the clinical efficacy, symptoms and the blood biochemical indicators were improved significantly than that of Western medicines alone on rheumatoid arthritis. At the same time, it can reduce adverse effects and enhance safety.
文摘目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服利用度(oral bioavailability,OB)、类药性(drug-likeness,DL),药物半衰期(drug half-life,HL)检索柴胡桂枝干姜汤中柴胡、桂枝、干姜、黄芩、瓜蒌根、牡蛎、炙甘草的候选化合物及作用靶点信息,并通过Uniprot数据库将靶点校正为基因名;运用Genecards数据库获取腺样体肥大的相关靶点与基因,利用VENNY图获得柴胡桂枝干姜汤与腺样体肥大的交集靶点;STRING数据库来构建蛋白质相互作用PPI网络图;David数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和KEGG通路富集分析;Cytoscape软件进行网络靶点特性分析。结果:筛选出柴胡桂枝干姜汤候选化合物65个,转化为有效靶点288个,得到腺样体肥大相关靶点781个,匹配得到共有靶点118个。GO富集主要涉及597个生物学过程、60个细胞组成和106个分子功能,KEGG通路分析主要涉及112条通路。结论:柴胡桂枝干姜汤治疗腺样体肥大是通过多靶点多通路发挥作用的。